Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC). Subsequent line of treatment for BCG unresponsive HR NMIBC patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results